Technology System
NaviFUS has two products in development：
NaviFUS® Neuronavigator-guided transcranial focused ultrasound system
NaviFUS® – FUS system that uses ultrasound energy to open the BBB and for neuromodulation; the device has already passed preliminary safety testing.
NAVIRFA® Needle Tracking System
Precise Surgical Tracking Technology
NAVIRFA® – Optical 3D surgical guidance kit and software that can accurately visualize the spatial position of surgical needles in vivo through special imaging algorithms.
Partners & Investors
We are supported by great venture capital and healthcare investors, and we partner with international distributors, physicians, medical institutions, academic researchers, and patient advocacy groups around the world.
OUR PARTNERSHIPSINVESTOR RELATIONS
NaviFUS Latest News
See what we’ve been up to.
NaviFUS and Bracco Sign Cooperation Agreement for Precision FUS Treatment
NaviFUS (6872) and Bracco, the world’s leading brand of ultrasound imaging agents, officially signed a cooperation agreement recently (4/26). Bracco will provide its microbubble imaging agents as part of the NaviFUS system’s treatment to open the blood-brain barrier (BBB). As a technology platform, the NaviFUS System will be used in clinical trials of various brain cancers or neurological diseases and registrations for the treatment. It is expected that after obtaining the marketing authorization, Bracco will be responsible for supplying this microbubble OEM product and authorize NaviFUS to bundle it as a medical device consumable with its device for acoustic therapy sales.
Read more
Interview with Dr. Kuo-Chen Wei on Netflix K-Drama “Queen of Tears”: Taiwan’s NaviFUS FUS Technology Spearheading Revolutionary Treatment for Glioblastoma
“Queen of Tears,” a recent popular Netflix K-Drama has been captivating global audiences with the tumultuous romance between its two main leads. It also happens to feature a look into some real innovative medical advancements in the treatment of brain tumors. The focused ultrasound treatment Hong Hae-in (Kim Ji-won) receives for her glioblastoma has been utilized in Taiwanese medtech firm NaviFUS’ clinical trials for the last few years and highlights Taiwan’s role as a leader in focused ultrasound advancements for the treatment of brain cancer.
Read more
First Participant Receives Sonodynamic Therapy for Glioblastoma in New Clinical Trial
Key Points:
– A new clinical trial is investigating sonodynamic therapy for patients with recurrent glioblastoma.
– This is the first clinical trial in the US to use the NaviFUS device, which combines neuronavigation with a mobile, noninvasive focused ultrasound system.
Contact NaviFUS
Thank you for your interest in NaviFUS.
Feel free to contact us with any questions regarding collaboration.